Evaluation of the Oral Bioavailability of Low Molecular Weight Heparin Formulated With Glycyrrhetinic Acid as Permeation Enhancer.
Low molecular weight heparin (LMWH) is the agent of choice for anticoagulant therapy and prophylaxis of thrombosis and coronary syndromes. However, its therapeutic use is limited due to poor oral bioavailability. The aim of this study was to investigate the oral delivery of LMWH, ardeparin formulated with 18-beta glycyrrhetinic acid (GA), as an alternative to currently used subcutaneous (sc) delivery. Drug transport through Caco-2 cell monolayers was monitored in the presence and absence of GA by scintillation counting and transepithelial electrical resistance. Regional permeability studies using rat intestine were performed using a modified Ussing chamber. Cell viability in the presence of various concentrations of enhancer was determined by MTT assay. The absorption of ardeparin after oral administration in rats was measured by an anti-factor Xa assay. Furthermore, the eventual mucosal epithelial damage was histologically evaluated. Higher ardeparin permeability (~7-fold) compared to control was observed in the presence of 0.02 % GA. Regional permeability studies indicated predominant absorption in the duodenal segment. Cell viability studies showed no significant cytotoxicity below 0.01 % GA. Ardeparin oral bioavailability was significantly increased (F(relative)/(S.C). = 13.3%) without causing any damage to the intestinal tissues. GA enhanced the oral absorption of ardeparin both in vitro and in vivo. The oral formulation of ardeparin with GA could be absorbed in the intestine. These results suggest that GA may be used as an absorption enhancer for the oral delivery of LMWH.
Motlekar
Nusrat A
NA
Srivenugopal
Kalkunte S
KS
Wachtel
Mitchell S
MS
Youan
Bi-Botti C
BB
N Engl J Med. 2001 Mar 1;344(9):626-31
11228276
Am J Hematol. 2001 May;67(1):10-4
11279651
Cardiovasc Surg. 2001 Jun;9(3):211-8
11336843
Biol Pharm Bull. 1994 Oct;17(10):1399-403
7874064
J Vasc Surg. 1999 Sep;30(3):526-31
10477646
Pharm Res. 1994 Aug;11(8):1132-42
7971714
Chem Pharm Bull (Tokyo). 1982 Jun;30(6):2245-7
7127610
J Drug Target. 1998;5(3):215-23
9606011
Drug Dev Ind Pharm. 2002 Sep;28(8):1033-41
12378958
Am J Physiol. 1991 Aug;261(2 Pt 1):G312-9
1872400
J Pharm Pharmacol. 1996 Dec;48(12):1285-9
9004192
J Pharm Sci. 1969 Nov;58(11):1372-5
5349752
Endocrinol Jpn. 1967 Mar;14(1):39-42
6072412
Biol Pharm Bull. 1995 Apr;18(4):566-70
7655429
J Pharm Pharmacol. 1999 Nov;51(11):1241-50
10632081
J Pharm Sci. 1997 Oct;86(10 ):1105-10
9344165
Thromb Res. 1989 Oct 1;56(1):119-24
2595670
Pharm Res. 1999 Jan;16(1):80-6
9950283
Chem Pharm Bull (Tokyo). 1992 Jun;40(6):1559-62
1394677
Am J Physiol. 1999 Sep;277(3 Pt 1):C554-62
10484342
Am J Physiol. 1987 Jan;252(1 Pt 2):F188-97
3101512
Pharm Res. 1988 Jun;5(6):341-6
3244645
J Pharmacobiodyn. 1989 Jan;12(1):31-6
2656985
J Pharm Sci. 2000 Apr;89(4):429-42
10737905
J Cell Physiol. 1995 Sep;164(3):533-45
7650061
Thromb Res. 1976 Mar;8(3):413-6
1265712
Haemostasis. 1995 Nov-Dec;25(6):288-98
8586320
Baillieres Clin Haematol. 1990 Jul;3(3):651-84
2148697
Pharm Res. 2001 Nov;18(11):1638-41
11758776
J Pharm Sci. 1995 Jun;84(6):682-7
7562404
Biomacromolecules. 2005 Jan-Feb;6(1):168-73
15638517
AAPS J. 2004 Oct 21;6(4):e31
15760096
Wien Med Wochenschr. 2003;153(19-20):426-33
14648923
Biochem J. 1988 Dec 15;256(3):1039-41
3146979
J Pharm Sci. 2004 Dec;93(12):2985-93
15468328
Curr Drug Deliv. 2005 Jul;2(3):277-87
16305430